Positive topline results from a Phase 2 study investigating tilrekimig
Pfizer today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the…
FDA approved HERNEXEOS®
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an…
FDA granted full approval to BRAFTOVI® in combination with cetuximab and fluorouracil-based chemotherapy
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF…
Positive topline results from a Phase 2 study investigating tilrekimig
Pfizer today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating…
Positive Phase 3 results for Gazyva®/Gazyvaro® in primary membranous nephropathy
Roche announced that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with Gazyva®/Gazyvaro® (obinutuzumab). Results show…
FDA approved HERNEXEOS®
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an…
Novartis announced that it has successfully completed its acquisition of Avidity
Novartis AG today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. “Avidity’s breakthrough science combined with Novartis capabilities will…
Servier launched a global partnership with Women in Tech
To turn ambition into action, Servier launched a global partnership with Women in Tech, which aims to reach 5 million women and girls in Science, Technology, Engineering and Mathematics (STEM)…
Pfizer launches cost savings program on TrumpRx
Pfizer today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range…
Novartis announced that it has successfully completed its acquisition of Avidity
Novartis AG today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. “Avidity’s breakthrough science combined with Novartis capabilities will…
GSK completes acquisition of RAPT Therapeutics
GSK announced the completion of its previously announced acquisition of RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal…